206 related articles for article (PubMed ID: 28323777)
21. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
22. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
23. Muir-Torre Syndrome: expanding the genotype and phenotype--a further family with a MSH6 mutation.
Murphy HR; Armstrong R; Cairns D; Greenhalgh KL
Fam Cancer; 2008; 7(3):255-7. PubMed ID: 18236172
[TBL] [Abstract][Full Text] [Related]
24. The role of immunohistochemistry in the Muir-Torre Syndrome.
Oliveira CM; Campos JG; Maia MR; Lobo LE; Valle FF
An Bras Dermatol; 2015; 90(3 Suppl 1):168-70. PubMed ID: 26312706
[TBL] [Abstract][Full Text] [Related]
25. Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3'UTR of the MSH6 gene.
Cini G; Carnevali I; Sahnane N; Chiaravalli AM; Dell'Elice A; Maestro R; Pin E; Bestetti I; Radovic S; Armelao F; Viel A; Tibiletti MG
Cancer Genet; 2021 Jun; 254-255():1-10. PubMed ID: 33516942
[TBL] [Abstract][Full Text] [Related]
26. Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.
Neelakantan IV; Di Palma S; Smith CE; McCoombe A
Head Neck Pathol; 2016 Sep; 10(3):354-61. PubMed ID: 26577210
[TBL] [Abstract][Full Text] [Related]
27. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
28. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
29. Molecular Genetics of Sebaceous Neoplasia.
North JP
Surg Pathol Clin; 2021 Jun; 14(2):273-284. PubMed ID: 34023105
[TBL] [Abstract][Full Text] [Related]
30. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management.
John AM; Schwartz RA
J Am Acad Dermatol; 2016 Mar; 74(3):558-66. PubMed ID: 26892655
[TBL] [Abstract][Full Text] [Related]
31. Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature.
Lee N; Luthra R; Lopez-Terrada D; Wang WL; Lazar AJ
J Cutan Pathol; 2013 Aug; 40(8):730-3. PubMed ID: 23672746
[TBL] [Abstract][Full Text] [Related]
32. Biallelic MYH germline mutations as cause of Muir-Torre syndrome.
Guillén-Ponce C; Castillejo A; Barberá VM; Pascual-Ramírez JC; Andrada E; Castillejo MI; Guarinós C; Molina-Garrido MJ; Carrato A; Soto JL
Fam Cancer; 2010 Jun; 9(2):151-4. PubMed ID: 19998059
[TBL] [Abstract][Full Text] [Related]
33. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
34. Muir-Torre syndrome caused by exonic deletion of MLH1 due to homologous recombination.
Shiki M; Hida T; Sugano K; Kaneko R; Kamiya T; Sakurai A; Yamashita T
Eur J Dermatol; 2017 Feb; 27(1):54-58. PubMed ID: 28120777
[TBL] [Abstract][Full Text] [Related]
35. Intraductal sebaceous papilloma of a meibomian gland: a new entity possibly associated with the MSH6 subtype of the Muir-Torre syndrome.
Jakobiec FA; Cortes Barrantes P; Lefebvre DR; Milman T
Surv Ophthalmol; 2020; 65(2):227-238. PubMed ID: 31557488
[TBL] [Abstract][Full Text] [Related]
36. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract][Full Text] [Related]
37. Muir-Torre Syndrome with Novel Mutation in the MSH2 Gene.
Ustaoglu E; Agirgol S; Aymelek HS; Turhan EI
Acta Dermatovenerol Croat; 2023 Dec; 31(3):144-147. PubMed ID: 38439724
[TBL] [Abstract][Full Text] [Related]
38. Lynch Syndrome and Muir-Torre Syndrome: An update and review on the genetics, epidemiology, and management of two related disorders.
Le S; Ansari U; Mumtaz A; Malik K; Patel P; Doyle A; Khachemoune A
Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447627
[TBL] [Abstract][Full Text] [Related]
39. Myxofibrosarcoma harboring an MLH1 pathogenic germline variant associated with Muir-Torre syndrome: a case report.
Nakagawa M; Kobayashi E; Yamada M; Watanabe T; Hirata M; Tanabe N; Ushiama M; Sakamoto H; Sato C; Mori T; Yoshida A; Yoshida T; Sugano K; Kawai A
Hered Cancer Clin Pract; 2021 Aug; 19(1):34. PubMed ID: 34419117
[TBL] [Abstract][Full Text] [Related]
40. Metachronous occurrence of colorectal cancer in a muir-torre syndrome patient presenting with recurrent sebaceous adenoma of the eyelid: case report and updated review of the literature.
Agiannidis C; Pana ZD; Molyva D; Kalokasidis K; Mixiou M
J Cutan Med Surg; 2012; 16(6):394-9. PubMed ID: 23149194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
